Drug Substance and Former Structure Property Relationships in 15 Diverse Pharmaceutical Co-Crystals

被引:75
作者
Stanton, Mary K. [1 ]
Tufekcic, Sunita [1 ]
Morgan, Carrie [1 ]
Bak, Annette [1 ]
机构
[1] Amgen Inc, Dept Pharmaceut, Cambridge, MA 02139 USA
关键词
COCRYSTALS; SOLUBILITY; ACID; CARBAMAZEPINE; ANTAGONISTS; SELECTION; IMPROVE; PHASES; STATE;
D O I
10.1021/cg8005019
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The pharmaceutical co-crystal approach can be used to modify physicochemical properties of new chemical entities. However, methodical studies of how co-crystal former selection influences properties of the resulting co-crystal, such as melting point and solubility, are needed. Consequently, we investigated 15 co-crystals of AMG 517 and three related molecules using di-and triacids as well as amides as co-crystal formers. Fourteen co-crystals and one partial salt were prepared as judged by pK(a) values and single crystal data. In addition, we found that our ability to form co-crystals was significantly influenced by even minor changes to the chemical structure of the drug substance. Furthermore, we discovered that all AMG 517 co-crystals, which we obtained single crystal structure for, utilize the same hydrogen bond donor (amide) and acceptor (benzothiazole) on the drug substance. Additional hydrogen bonds were observed in all of the co-crystals. In this study, we found little correlation between the melting point of the co-crystal former and the co-crystal, and no correlation between the melting point and solubility of the co-crystals, although some correlations within specific classes were found. Therefore, as the diversity of co-crystal formers increases, rational design of AMG 517 co-crystals becomes more difficult, and obtaining the desired physicochemical properties would still have to involve experimental testing.
引用
收藏
页码:1344 / 1352
页数:9
相关论文
共 35 条
[1]   2-Acetaminopyridine:: A highly effective cocrystallizing agent [J].
Aakeröy, CB ;
Hussain, I ;
Desper, J .
CRYSTAL GROWTH & DESIGN, 2006, 6 (02) :474-480
[2]   Crystal engineering of the composition of pharmaceutical phases.: Do pharmaceutical co-crystals represent a new path to improved medicines? [J].
Almarsson, Ö ;
Zaworotko, MJ .
CHEMICAL COMMUNICATIONS, 2004, (17) :1889-1896
[3]  
BAK A, 2008, ENH SOL BIOAV C FRAN, P24313
[4]   The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics [J].
Bak, Annette ;
Gore, Anu ;
Yanez, Evelyn ;
Stanton, Mary ;
Tufekcic, Sunita ;
Syed, Rashid ;
Akrami, Anna ;
Rose, Mark ;
Surapaneni, Sekhar ;
Bostick, Tracy ;
King, Anthony ;
Neervannan, Sesha ;
Ostovic, Drazen ;
Koparkar, Arun .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2008, 97 (09) :3942-3956
[5]   The salt-cocrystal continuum: The influence of crystal structure on ionization state [J].
Childs, Scott L. ;
Stahly, G. Patrick ;
Park, Aeri .
MOLECULAR PHARMACEUTICS, 2007, 4 (03) :323-338
[6]   Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids [J].
Childs, SL ;
Chyall, LJ ;
Dunlap, JT ;
Smolenskaya, VN ;
Stahly, BC ;
Stahly, GP .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (41) :13335-13342
[7]  
Cooke M. W., 2007, AM PHARM REV, V10, P54
[8]   Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate [J].
Doherty, Elizabeth M. ;
Fotsch, Christopher ;
Bannon, Anthony W. ;
Bo, Yunxin ;
Chen, Ning ;
Dominguez, Celia ;
Falsey, James ;
Gavva, Narender R. ;
Katon, Jodie ;
Nixey, Thomas ;
Ognyanov, Vassil I. ;
Pettus, Liping ;
Rzasa, Robert M. ;
Stec, Markian ;
Surapaneni, Sekhar ;
Tamir, Rami ;
Zhu, Jiawang ;
Treanor, James J. S. ;
Norman, Mark H. .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (15) :3515-3527
[9]   HYDROGEN-BONDS AS DESIGN ELEMENTS IN ORGANIC-CHEMISTRY [J].
ETTER, MC .
JOURNAL OF PHYSICAL CHEMISTRY, 1991, 95 (12) :4601-4610
[10]   Crystal engineering of the composition of pharmaceutical phases:: Multiple-component crystalline solids involving carbamazepine [J].
Fleischman, SG ;
Kuduva, SS ;
McMahon, JA ;
Moulton, B ;
Walsh, RDB ;
Rodríguez-Hornedo, N ;
Zaworotko, MJ .
CRYSTAL GROWTH & DESIGN, 2003, 3 (06) :909-919